|
Ning
Wang, Xue-Qin Gao, Jin-Xiang Han, Shandong Medicinal
Biotechnological Center, Shandong Academy of Medical Sciences; Key
Laboratory for Biotechdrugs, Ministry of Public Health, Jinan
250062, Shandong Province, China
Supported by the National Key Technology Research and
Development Program of China during the 9th Five-Year Plan Period,
No. 96C020117
Correspondence to: Professor
Jin-Xiang Han, Shandong Medicinal Biotechnological Center, Shandong
Academy of Medical Sciences; Key Laboratory for Biotechdrugs,
Ministry of Public Health, Jinan 250062, Shandong Province, China.
jxhan@sdu.edu.cn
Telephone: +86-531-2919888
Received: 2003-08-23
Accepted: 2003-10-07
Abstract
AIM: To design and establish a method of multiplex PCR
normalization for simultaneously detecting HBV and HCV.
METHODS: Two pairs of primers with a 20 bp joint sequence were used
to amplify the target genes of HBV and HCV by two rounds of
amplification. After the two rounds of amplification all the
products had the joint sequence. Then the joint sequence was used as
primers to finish the last amplification. Finally multiplex PCR was
normalized to a single PCR system to eliminate multiplex factor
interference. Four kinds of nucleic acid extraction methods were
compared and screened. A multiplex PCR normalization method was
established and optimized by orthogonal design of 6 key factors.
Then twenty serum samples were detected to evaluate the validity and
authenticity of this method.
RESULTS: The sensitivity, specificity, diagnostic index and
efficiency were 83.3%, 70%, 153.3% and 72.2%, respectively for both
HBsAg and anti-HCV positive patients, and were 78.6%, 80%, 258.6%
and 79.2%, respectively for HBsAg positive patients, and were 75%,
90%, 165% and 83.3%, respectively for anti-HCV positive patients.
CONCLUSION: The multiplex PCR normalization method shows a broad
prospect in simultaneous amplification of multiple genes of
different sources. It is practical, correct and authentic, and can
be used to prevent and control HBV and HCV.
Wang N, Gao XQ, Han JX.
Simultaneous detection of HBV and HCV by multiplex PCR
normalization. World J Gastroenterol
2004; 10(16): 2439-2443
http://www.wjgnet.com/1007-9327/10/2439.asp
INTRODUCTION
Multiplex PCR uses several pairs of primers that target
different genes to simultaneously amplify several different target
sequences at a high speed and with a high efficiency. As many
amplification factors may interact and produce non-specific
amplification, its clinical use is limited. According to the
characteristics of a small fragment that did not complement to the
genes of PCR primers, we established a multiplex PCR normalization
method (This method has been patented in the Chinese Patent Agency).
By creating a primary reaction that was appropriate to all target
templates, the multiplex was normalized to a single target PCR. This
method could overcome the difficulties in establishing and
optimizing the multiplex reaction system. In this article the
practicality and effectiveness of multiplex PCR were validated by
simultaneous detection of HBV and HCV.
MATERIALS AND METHODS
Specimen collection
Twenty-eight serum samples were collected from Jinan Central
Hospital and Jinan Infectious Disease Hospital. The samples were all
validated by ELISA method, in which 14 cases were HBsAg (+), 8 were
anti-HCV (+), and 6 were positive for both HBsAg and anti-HCV.
Ten cases were negative for both HBsAg and anti -HCV and used
as control.
Reagents
and instruments
HBV
PCR kits and HCV PCR kits were purchased from Institutes of Liver
Diseases, Peking University Medical College. dNTPs, AMV, proteinase
K, isothiocyanate guanidine and Triton X ×100 were products of TAKARA. PCR Amplification MinicyclerTM
was from MJ Research, USA. Innotech ImagerTM 2200 was
from Alpha Innotech Incoporation.
Extraction
of virus nucleic acids
Method 1[1]: Proteinase K (10 mg/mL) was added to 150 mL
serum and incubated at 50 °C for 2 h. RNA and DNA were extracted with phenol-chloroform at
pH4.0 and 8.0 respectively, and then nucleic acids were precipitated
with Isopropyl alcohol. The final pellets were dissolved in 10 mL
RNase free water and stored at -70 °C.
Method 2[2]: 200 mL
guanidine isothiocynate and 20 mL
glass powder were added to 200 mL
serum and incubated at ambient temperature for 90 min and
centrifuged at 12 000 g. The supernatant was removed and the pellet
was washed and dissolved in reverse transcription buffer PCR
detection.
Method 3[3]: 90 mL
lytic buffer (120 g GUSCN, 100 mL 0.1mol/L Tris-HCl, pH6.4), 0.2
mol/L EDTA (20 mL,
pH8.0) and glass powder were added to 50 mL
serum and incubated at room temperature for 10 min, mixed and
centrifuged at 12 000 g for 15 s, washed 2 times with washing
solution (120 g GUSCN, 100 mL 0.1 mol/L
Tris-HCl, pH 6.4, 2.6 g Triton ×100),
and further washed with 700 mL/L ethanol and acetone. Then acetone
was removed and dried at 56 °C
for 10 min and TE buffer was added to the pellets and
incubate at 56 °C
for 2 min and then
centrifuged for 2 min.
The supernatant was transferred to another tube for further
amplification.
Method 4[4]: 200 mL
lytic buffer[6 mol/L guanidine hydrochloride, 10 mmol/L
Tris-HCl (pH 7.5), 200 g/L Triton X-100 (pH 4.4)], and 10
mmol/L urea, were added to 200 mL
serum, proteinase K 40 mL,
glass powder 10 mg,
and incubated in 72 °C
water bath for 10 min, then 100 mL
Isopropyl alcohol was added and centrifuged at 8 000 r/min
for 1 min. The supernatant was removed, and washed with 100 mL
washing solution [20 mmol/L NaCl,
20 mmol/L Tris-HCl (pH7.5) and 1 000 mL/L
ethanol] and centrifuged at 8 000 r/min
for 1 min. The supernatant was removed and washed and
centrifuged at 8 000 r/min for 1 min and 13 000 g for 10 s, dried
and dissolved in 50 mL
RNase free water.
Primer
design
The primers for the first round of PCR: HBV reverse primer:
5’-GAT GAT GGG ATG GGA ATA CA-3’ (position: 2 566-2 586 of P
gene), HBV RT primer: 5’-GCT GGT TCA CAT TGT GAG GGG AGT CTA GAC
TCG TGG TGG A-3’ with the former 20 bp as the joint sequence, and
the latter 20 bp in the position of the overlap of genome P region
and Pre-S region (position 2 921-2 941). There was a 395 bp between
R and RT primers. HCV reverse primer: 5’-ATC ACT CCC CTG TGA GGA
A-3’ which was located between 47-65 bp. RT -PCR primer: 5’-GCT
GGT TCA CAT TGT GAG GGC TAC GAG ACC TCC CGG GGC A-3’. The former
20 bp was the joint sequence, the latter 20 bp was in 313-332 of HBV
genome. The product between R and RT primers was a 315 bp fragment.
The second round primers: N primer sequence was 5’-GCT GGT TCA CAT
TGT GAG GG TAG AGG ACA AAC GGG CAA CA3’, the former 20 bp was the
joint sequence, and the latter 20 bp was in 2 703-2 723 of HBV
genome. RT-PCR primer was the same as that of the first round, the
amplification product was a 278 bp fragment between N and RT. The
HCV N primer was 5’-GCT GGT TCA CAT TGT GAG GG GGG AGA GCCAT AGT
GGT CTG-3’, the former 20 bp was the joint sequence, and the
latter 20 bp was located between 132-151 of HCV. RT primers were the same as the first round of amplification
and the product was a 241 bp fragment. After two rounds of
amplification, the third round was amplified with the common primers
T: 5’GCT GGT TCA CAT TGT GAG GG3’. The primers were synthesized
by phosphoamidite method with 391 DNA synthesizer. The synthesized
primers were purified with OPC column[5].
Quality
evaluation parameters of designed diagnostic assay
Sensitivity indicated the percent of positive cases by the
diagnostic assay in the patient group. It was calculated according
to the following formula.
| Sensitivity
= |
True
positivity |
×100% |
| True
positive + false negative |
The
sensitivity should be 100% for a perfect diagnostic assay.
Specificity indicated the percent of negative cases
determined by the diagnostic assay in control group. It was
calculated according to the following equation.
| Specificity
= |
True
negativity |
×100% |
| False
positivity +true negativity |
The
specificity should be 100% for a perfect diagnostic assay.
Diagnostic index was
a combined parameter to evaluate the sensitivity and specificity. It
was the sum of sensitivity and specificity. The perfect diagnostic
index should be 200%, and it should not be lower than 100%.
Agreement rate indicated
the ability of a diagnostic assay to correctly discern the patients
and control cases. It was calculated by the following method. The
perfect agreement rate of a diagnostic assay should be 100%.
| Agreement
rate = |
TP+TN |
×100% |
| TP+FP+TN+FN |
(TP:
true positivity; TN: true negativity; FP: false positivity; FN:
false negativity).
Positive predictive value (PPV)
indicated the percent of patients in the positive results of
diagnostic assay. It was calculated according to the following
equation.
Negative
predictive value (NPV) indicated
the percent of non-patients in the negative results of diagnostic
assay. It was calculated according to the following equation.
(NPV:
negative predictive value; TN: true negativity; FN: false
negativity; TN: true negativity).
RESULTS
Screening extraction methods for HBV DNA from HBsAg positive
serum
Four methods were used to extract HBV DNA from HBsAg
positive sera of patients. The results of amplification were
compared to that of ELISA (Table 1).
The positive amplification rates were 20%, 60%, 85% and 95%
for methods 1 to 4 respectively.
Screening
the extracting methods of HCV RNA from anti-HCV positive serum
Fifteen anti-HCV positive sera were extracted with the four
methods and the results were compared with ELISA (Table 2).
The positive amplification rates were 6%, 6%, 30% and 95% for
methods 1 to 4, respectively compared to the ELISA.
Establishment
of simultaneous extraction method of HBVDNA and HCV RNA
Six samples positive for both HBsAg and anti-HCV were
extracted and amplified, the simultaneous extraction positive rate
was 100% for HBV and
83% for HCV, respectively.
Table
1 Amplification
results of HBV DNA from 20 HBsAg positive sera
| Method |
Sample
number |
| 1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
19 |
20 |
| ELISA |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
| Method
1 |
- |
- |
+ |
+ |
+ |
- |
+ |
- |
- |
- |
- |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
| Method
2 |
+ |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
- |
+ |
+ |
+ |
- |
- |
- |
+ |
+ |
- |
- |
| Method
3 |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
- |
- |
+ |
+ |
+ |
+ |
- |
+ |
+ |
+ |
+ |
| Mrthod
4 |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
- |
+ |
+ |
Note:
+ represents positive amplification; - represents negative
amplification.
Table
2 Amplification
results of HCV RNA from 15 anti-HCV positive sera
| Method |
Sample
number |
| 1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
| ELISA |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
| Method
1 |
- |
- |
- |
- |
- |
- |
- |
- |
+ |
- |
- |
- |
- |
- |
- |
| Method
2 |
- |
- |
- |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Method
3 |
- |
+ |
+ |
+ |
- |
- |
- |
- |
+ |
+ |
- |
- |
+ |
- |
- |
| Method
4 |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
- |
+ |
+ |
+ |
+ |
Note:
+ represents positive amplification; - represents negative
amplification.
Establishment
of RT and first round of amplification method
Orthogonal
method was used to select the six common factors affecting the
amplification, which were the concentrations of dNTPs, Mg2+,
Taq polymerase, AMV and primers (including HBV and HCV). Five levels
were designed for each factor. The pattern of orthogonal was L 25[5,6].
The PCR reaction was as follows: HBV, 8 mL
HCV template, 5 mL
10×buffer,
40 U RNase inhibitor, and other components and finally ddH2O
was added to make the total volume 50 mL.
Twenty-five kinds of amplification system were available. After
paraffin oil was added, reactions were performed at
50 °C for 30 min, at 95
°C for 2 min,and 30 cycles at 95 °C for 30 s, at 55 °C for 30 s, at 72 °C for 1 min. Then 10 mL
amplification product was identified by 15 g/L agarose
electrophoresis. The results showed under the condition of protocol
13, that both HBV and HCV targets were successfully amplified,
therefore protocol 13 was chosen as the first round protocol. The
amplification program was at 50 °C for 30 min, at 95 °C for 2 min, and at 95 °C for 30 s, at 55 °C for 30 s and at 72 °C for 1 min for a total of 30 cycles.
Screening
of the second round of amplification reaction condition
According to the orthogonal method and experience, 6
protocols were designed. The reaction condition was at 95 °C
for 30 s, at 55 °C
for 30 s, and at 72 °C
for 45 s for a total of 10 cycles. The results showed that the two
target bands of HBV and HCV were successfully separated in protocol
1. Therefore the protocol 1 was chosen as the final optimal
protocol.
Screening of the third round of amplification reaction
According to the results of the above two rounds of
amplification, 7 protocols were designed for the third round of
amplification. All the amplification reactions were done at 95 °C
for 30 s, at 55 °C
for 30 s, at 72 °C
for 1 min for a total of 30 cycles. The results showed that the HBV
and HCV target bands were discerned more obviously under the
condition of protocol 2, which was therefore determined as the
optimal protocol.
Comparison of normalized PCR detection results with ELISA
method
Twenty-eight samples were detected with both normalized PCR
method and ELISA method. In the 14 samples positive for HBsAg, the
results of the six antibody-positive amplifications are shown in
Figure 1. The concordance of PCR with ELISA was 78.8%. Eight anti-HCV
positive samples detected with multiplex PCR had a coincidence rate
of 75% compared with ELISA method. When it was used to detect
samples positive for both HBsAg and anti-HCV, the coincidence rate
was 83.3%. Ten control cases negative for both HBsAg and anti-HCV
were also detected with normalized PCR, of which 2 were positive for
HBV and 1 for HCV.
Quality evaluation of simultaneous PCR detection of HBV and
HCV
Fourteen patients with HBV infection were detected with
normalized PCR method. The results showed that the true positivity
was 11 and the false negativity was 3 (Table3).
Figure 1(PDF)
Normalized PCR amplification for patients with both HBsAg and
anti-HCV antibodies. M represents X174-hae III marker. Lanes 1 to 6
represent amplification results of six patients who were positive
for HBsAg and anti-HCV. Only lane 2 is negative for HCV.
Of
the eight HCV patients detected with normalized method, 6 were
positive and 2 were negative. Six patients with both HBV and HCV
infection were also detected, of which 5 were positive and 1 was
negative (Figure 1 and Table 4). Ten patients without HBsAg and
anti-HCV infection were also detected with our method, of which 8
were negative for HBV and 2 were positive for HBV (false positivity),
9 were negative for HCV and 1 positive for HCV (false positivity)
(Tables 3, 4).
Evaluation
of validity and diagnostic power of normalized PCR for detecting HBV
DNA
The sensitivity of this method for the detection of HBV DNA
was 78.6% (11/14). The
specificity was 80% (8/10). The diagnostic index was 158.6% (78.6%
plus 80%) and the agreement rate was 79.2%. The positive predictive
value was 84.6% (11/13). The negative predictive value was 72.7%
(8/11) (Table 3).
Table
3 Evaluation of
validity and diagnostic power of normalized PCR for detecting HBV
DNA
|
HBV
patient |
Non-HBV
control |
Total |
| Positive |
11 |
2 |
13 |
| Negative |
3 |
8 |
11 |
| Total |
14 |
10 |
24 |
Table
4 Evaluation of
validity and diagnostic power of normalized PCR for detecting HCV
RNA
|
HCV
patients |
Non-HCV
control |
Total |
| Positive |
6 |
1 |
7 |
| Negative |
2 |
9 |
11 |
| Total |
8 |
10 |
18 |
Quality
evaluation of validity and diagnostic power of normalized PCR for
detecting HCV RNA
The sensitivity of this method for the detection of HCV RNA
was 75% (6/8). The
specificity was 90% (9/10). The diagnostic index was 165% (75% plus
90%) and the diagnostic efficiency was 83.3%. The positive
predictive value was 85.7% (6/7). The negative predictive value was
81.8% (9/11) (Table 4).
Evaluation
of validity and diagnostic power of normalized PCR for detection of
both HBV DNA and HCV RNA
The sensitivity of this method for the detection of
superinfection of HBV DNA and HCV RNA was 83.3% (5/6). The
specificity was 70% (7/10). The diagnostic index was 153.3% (83.3%
plus 70%) and the diagnostic efficiency was 72.2%. The positive
predictive value was 62.5%. The negative predictive value was 87.5%
(Table 5).
Table 5 Evaluation
of validity and diagnostic power of normalized method for detecting
HBV and HCV double infection
|
HBV(+)and
anti-HCV(+) |
HBV(-)
and anti-HCV(-) |
Total |
| Positive |
5 |
8 |
13 |
| Negative |
1 |
2 |
3 |
| Total |
6 |
10 |
16 |
DISCUSSION
Virus particles of HBV and HCV are rare in blood and HCV RNA is
easily to degrade, therefore selecting protein denaturing agents to
quickly dissolve the membrane protein is very important in the
process of simultaneous extraction of HBV and HCV nucleic acids. Our
results showed that method 4 was the most effective among the four
extraction methods. The effective extraction rate was 95% for both
HBsAg and anti-HCV positive serum. In method 4, hydrochloride
guanine was a potent protein denaturant, it could dissolve the
protein and destruct its secondary structure and cell structure, and
mad it possible to separate nucleotide protein from nucleic acids.
Urea and Triton X-100 are non-detergents and could dissolve cell
membrane and precipitate the protein. Proteinase K could further
degrade protein. Glass powder had absorptive effect on nucleic acids
and therefore could absorb nucleic acids on its surface. Isopropyl
alcohol could precipitate nucleic acids and finally the low ion
potential solution could elute nucleic acids from the glass powder.
This method was confirmed to be effective and authentic, suitable
for the separation of virus RNA and DNA. In practice, it was a
simple, fast, stable and reproducible method.
Theoretically, there is no limit on the number of target
sequences simultaneously amplified by multiplex PCR. But the
stringency of specific conditions restricted the number of target
sequences amplified. In order to overcome these limits, we
established a multiplex normalized amplification method. First a
nested PCR amplification was performed with 2 pairs of primers with
a joint sequence. Then a normalized amplification was done with
joint primers. The effects of competition of primers were the
lowest, so that the multiplex PCR became a single target PCR. These
measurements could overcome the difficulties in establishing and
optimizing the conditions of multiplex PCR. The success of this
method has shed some lights on the development of PCR techniques. We
used the orthogonal method for the design of experiment[6],
and divided the key factors of PCR reaction such as primer
concentration, dNTPs, Taq polymerase, AMV and magnesium chloride
concentration into different grades, and a factor table was set up.
This included all possible arrangements and combination of factors.
The results showed that the coordination of proportion of the 6
factors was very important. If the proportion of HBV and HCV primers
was not appropriate, and sometimes one of the amplifications was
superior to another and only one band could be identified by
electrophoresis.
ELISA
is a method to detect antibody for the purpose of diagnosis of virus
infection. The antibody was only detected 1 to 2 wk after infection,
which reflected the immune response of the host, but could not
explain the virus replication. PCR method could directly detect the
virus nucleic acids. It could reflect the state of virus
replication. When the virus was cleaned up, only the antibody was
positive, the nucleic acids could not be detected. That is why the
detection rate of PCR was lower when ELISA was used as a golden
standard. In this study, 1/8 of the anti-HCV patients were negative
for HCV RNA, and 1/ 6 patients were positive for both HBsAg and HCV,
which were undetectable by our method. This is partly because the
patients were in the state of convalescence, and the virus was
already cleaned up or was false positive for ELISA due to
hyperimmu-noglobulinemia, rheumatoid factor and superoxide dismutase.
The detection of HCV RNA in non-hepatitis patients could be
explained by the fact that the patients might be in the early stage
of acute hepatitis, and the antibody had not been produced yet. A
close follow-up is needed for the early diagnosis and treatment
after the possibility of false positive is excluded.
Currently,
the super-infection rate of HBV and HCV was very high, and it was
13.64% to 27.27% reported by Xu[7]. It is important to
establish methods that can simultaneously detect combined virus
infection. Konomi et al.[8] reported a multiplex
polymerase chain reaction (PCR) method for simultaneous detection of
hepatitis B, C, and G viral genomes. The levels of concordance with
the data obtained by conventional single PCR method were 100% for
single infection, 98-100% for double infection, and 92% for triple
infection. Meng Q and his colleagues[9] established an
automatic multiplex system for simultaneously screening hepatitis B
virus (HBV), hepatitis C virus (HCV), and human immunodeficiency
virus type 1 (HIV-1) in blood donations. The detection limits (95%
confidence interval) were 22 to 60 copies/mL for HBV, 61 to 112 IU/mL
for HCV, and 33 to 66 copies/mL for HIV-1, using a specimen input
volume of 0.2 mL. The AMPLINAT MPX assay could detect a broad range
of genotypes or subtypes for all three viruses and had a specificity
of 99.6% for all three viruses with sero-negative specimens. In an
evaluation of sero-conversion panels, the AMPLINAT MPX assay
detected HBV infection an average of 24 d before the detection of
HBsAg by enzyme immunoassay. HCV RNA was detected an average of 31 d
before HCV antibody appeared. HIV-1 RNA was detected an average of
14 d before HIV-1 antibody and an average of 9 d before p24 antigen.
A Chinese group has designed a visual gene-detecting technique using
nanoparticle-supported gene probes. With the aid of gold
nanoparticle-supported 3’-end-mercapto-derivatized oligonucleotide
serving as a detection probe, and 5’-end -amino-derivatized
oligonucleotide immobilized on glass surface acting as a capturing
probe, target DNA was detected visually by sandwich hybridization
based on highly sensitive “nano-amplification” and silver
staining. Different genotypes of hepatitis B and C viruses in serum
samples from infected patients were detected using home made HBV,
HCV, and HBV/HCV gene chips by the gold/silver nanoparticle staining
amplification method. The present visual gene-detecting technique
might avoid limitations of the reported methods due to for its high
sensitivity, good specificity, simplicity, speed, and cheapness[10].
Multiplex
PCR assay has been used for the simultaneous detection of many
different genes of pathogens including genes related with antibiotic
resistance genes in Staphylococcus aureus[11]. A
multiplex reverse transcriptase polymerase chain reaction (RT-PCR)
was also applied for the simultaneous detection of hepatitis A virus
(HAV), poliovirus (PV) and simian rotavirus (RV-SA11), and compared
with specific primers for each genome sequence. Three amplified DNA
products representing HAV (192 bp), PV (394 bp) and RV (278 bp) were
identified when positive controls were used[12]. A
multiplex RT-PCR method was described for the simultaneous detection
of all four viruses in combination with a plant mRNA specific
internal control which could be used as an indicator of the
effectiveness of the extraction and RT- PCR. The upper detection
limit for the four viruses was at an extract dilution of 1/200[13].
A multiplex semi-nested PCR was developed for the simultaneous
detection and differentiation among porcine circovirus 1 (PCV1),
PCV2, and porcine parvovirus (PPV) from boar semen. Primers of PCV1,
PCV2 and PPV were specific and did not react with other viruses
respectively. Twenty (20.4%) and 42 (42.9%) out of 98 whole semen
samples were found to be positive for PCV and PPV using conventional
multiplex and semi-nested PCR respectively[14]. Multiplex
method for HBV/HCV/HIV-1 has been used for screening 6 805 010 units
of serologically negative donation and 112 HBV DNA-positives, 25 HCV
RNA positives and 4 HIV-1 RNA positives were screened out and
prevented transfusion of the positive blood[15,16].
The
sensitivity of our multiplex normalized PCR method was 78.6%, 75%
and 83.3% for the detection of HBVDNA, HCVRNA, and super-infection
of HBV and HCV respectively. The specificity was 80%, 90% and 70%,
respectively. These are good enough for a diagnostic assay. It can
detect both DNA and RNA simultaneously and can be completed in one
day. It is not only suitable for clinical diagnosis, but also
suitable for the screening of HBV and HCV from blood donators to
prevent the transmission of these diseases. It can also be used for
an epidemiological study. In these respects it needs to be further
studied in a large-scale population.
REFERENCES
1
Hu KQ, Yu CH, Lee S, Villamil FG, Vierling JM. Simultaneous
detection of both hepatitis B virus DNA and hepatitis C virus
RNA using a combined one-step
polymerase chain reaction technique. Hepatology 1995; 21: 901-907
2
Yamada O, Matsumoto T, Nakashima M, Hagari S, Kamahora T,
Ueyama H, Kishi Y, Uemura H, Kurimura T. A new
method for extracting DNA or RNA for
polymerase chain reaction. J Virol Methods 1990; 27: 203-209
3
Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen
PM, van der Noordaa J. Rapid and simple method for
purification of nucleic acids. J Clin
Microbiol 1990; 28: 495-503
4
Vogelstein B, Gillespie D. Preparative and analytical
purification of DNA from agarose. Proc Natl Acad Sci U S A
1979; 76: 615-619
5
Han JX, Zhang C, Yang XC, Tang TH, Wang ML. Investigation on
the purification and synthesizing of DNA fragments by
OPC methods. Shandong Yike Daxue
Xuebao 1995; 33: 173-174
6
Fang JQ, Fu CZ, Liao RR. Regression methods of pair -wise
data. Zhongguo Weisheng Tongji 1996; 13: 1-5
7
Xu ZF, Xu KC, Meng XY. Investigation on the double infection
of HBV and HCV. Nantong Yixueyuan Xuebao
1994; 14: 162-165
8
Konomi N, Yamaguchi M, Naito H, Aiba N, Saito T, Arakawa Y,
Abe K. Simultaneous detection of hepatitis B, C, and G
viral genomes by multiplex PCR
method. Jpn J Infect Dis 2000; 53: 70-72
9
Meng Q, Wong C, Rangachari A, Tamatsukuri S, Sasaki M, Fiss
E, Cheng L, Ramankutty T, Clarke D, Yawata H,
Sakakura Y, Hirose T, Impraim C.
Automated multiplex assay system for simultaneous detection of
hepatitis B virus
DNA, hepatitis C virus RNA, and human
immunodeficiency virus type 1 RNA. J Clin Microbiol 2001; 39:
2937-2945
10
Wang YF, Pang DW, Zhang ZL, Zheng HZ, Cao JP, Shen JT. Visual
gene diagnosis of HBV and HCV based on
nanoparticle probe amplification and
silver staining enhancement. J Med Virol 2003; 70: 205-211
11 Strommenger B,
Kettlitz C, Werner G, Witte W. Multiplex PCR assay for simultaneous
detection of nine clinically
relevant antibiotic resistance genes
in Staphylococcus aureus. J Clin Microbiol 2003; 41: 4089-4094
12 Coelho C, Vinatea CE,
Heinert AP, Simoes CM, Barardi CR. Comparison between specific and
multiplex reverse
transcription-polymerase chain
reaction for detection of hepatitis A virus, poliovirus and
rotavirus in experimentally
seeded oysters. Mem Inst Oswaldo Cruz
2003; 98: 465-468
13
Thompson JR, Wetzel S, Klerks MM, Vaskova D, Schoen CD, Spak
J, Jelkmann W. Multiplex RT-PCR detection of four
aphid-borne strawberry viruses in
Fragaria spp. in combination with a plant mRNA specific internal
control. J Virol
Methods 2003; 111: 85-93
14
Kim J, Han DU, Choi C, Chae C. Simultaneous detection and
differentiation between porcine circovirus and porcine
parvovirus in boar semen by multiplex
seminested polymerase chain reaction. J Vet Med Sci 2003; 65:
741-744
15
Ohnuma H, Tanaka T, Yoshikawa A, Murokawa H, Minegishi K,
Yamanaka R, Lizuka HY, Miyamoto M, Satoh S,
Nakahira S, Tomono T, Murozuka T,
Takeda Y, Doi Y, Mine H, Yokoyama S, Hirose T, Nishioka K. The first
large-scale
nucleic acid amplification testing
(NAT) of donated blood using multiplex reagent for simultaneous
detection of HBV,
HCV, and HIV-1 and significance of
NAT for HBV. Microbiol Immunol 2001; 45: 667-672
16
Mine H, Emura H, Miyamoto M, Tomono T, Minegishi K, Murokawa
H, Yamanaka R, Yoshikawa A, Nishioka K. High
throughput screening of 16 million
serologically negative blood donors for hepatitis B virus, hepatitis
C virus and
human immunodeficiency virus type-1
by nucleic acid amplification testing with specific and sensitive
multiplex
reagent in Japan. J Virol Methods
2003; 112: 145-151
Edited
by
Wang
XL and Zhang JZ Proofread
by Xu FM
| |